表紙
市場調查報告書

接觸性皮膚炎(CD):市場分析,流行病學,市場預測(至2030年)

Contact Dermatitis (CD) - Market Insights, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 948124
出版日期 內容資訊 英文 200 Pages
商品交期: 最快1-2個工作天內
價格
接觸性皮膚炎(CD):市場分析,流行病學,市場預測(至2030年) Contact Dermatitis (CD) - Market Insights, Epidemiology and Market Forecast - 2030
出版日期: 2020年07月01日內容資訊: 英文 200 Pages
簡介

2017年,全球七個主要國家的接觸性皮膚炎(CD)市場規模估計為78.31億美元。美國是七個國家中最大的市場。在五個歐洲國家中,2017年德國的市場規模最大,為9.81億美元,最小的國家是西班牙,2017年為2.93億美元。 2017年,日本CD市場規模達到7.52億美元,預計在2020年至2030年的預測期內將增長。

該報告調查了全球七個主要市場(美國,德國,英國,意大利,法國,西班牙和日本)的接觸性皮炎(CD)市場,市場概況,疾病背景/流行病學和診斷。我們分析了指導原則,每個國家的市場前景以及影響市場增長的因素。

第1章主要見解

第2章市場概述:接觸性皮膚炎(CD)

  • 市場佔有率(%)2017
  • 2030年市場佔有率(%)

第3章執行摘要

第4章疾病的背景和概述:接觸性皮膚炎(CD)

  • 類型
    • 刺激性接觸性皮膚炎(ICD)
    • 過敏性接觸性皮膚炎(ACD)
    • 接觸性蕁麻疹
  • 原因
    • 金屬
    • 香味
    • 抗菌藥膏
    • 甲醛
    • 異塞唑林酮
    • 椰油□胺基丙基甜菜鹼
    • 對苯二胺
  • 症狀
  • 病理生理學
  • 診斷

第5章CD診斷/管理算法

第6章美國過敏,哮喘和免疫學學會(AAAAI)診斷指南

  • 臨床評估
  • 貼片測試建議
  • 暴露於臨床相關過敏原的來源
  • 外用CD
  • 特定年齡段
    • 兒科CD
    • 職業CD

第7章英國皮膚科醫生協會(BAD)診斷指南

  • 評估和調查
  • 診斷測試(診斷)
    • 準備病人
    • 貼片測試
    • 貼片測試測量時間
    • 積極的反應讀物和相關性
    • 照片貼片測試
    • 開放貼片測試

第8章流行病學和患者人群:主要發現

  • 7個主要市場:7個主要國家的接觸性皮膚炎患病率

第9章接觸性皮膚炎流行病學:按國家

  • 美國
  • 五個歐洲國家
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

第10章治療

第11章接觸性皮膚炎:臨床參數

  • CD的處理

第12章英國皮膚科醫生協會(BAD)CD管理指南2017年

  • 管理/治療選項
    • 避免
    • 保護
    • 替代
    • 永久性CD治療

第13章許可設施

第14章未滿足的需求

第15章新型治療劑

  • 競爭
  • EB01乳霜:Edessa Biotech
    • 產品說明
    • 其他發展活動
    • 臨床發展
    • 安全性和有效性
    • 產品簡介
  • PDC-APB:Hapten Sciences

第16章接觸性皮膚炎:7個主要市場的分析

  • 主要發現
  • 七個主要國家的接觸性皮膚炎市場規模

第17章美國市場展望

  • 美國市場規模
    • 接觸性皮膚炎的總市場規模
    • 按治療劑劃分的市場規模

第18章歐洲五個國家:市場前景

  • 德國
    • 接觸性皮膚炎的總市場規模
    • 按治療劑劃分的市場規模
  • 法國
  • 意大利
  • 西班牙
  • 英國

第19章日本市場展望

  • 日本市場規模
    • 接觸性皮膚炎的總市場規模
    • 按治療劑劃分的市場規模

第20章KOL評論

第21章案例報告

  • 小兒接觸性皮炎對小兒接觸性接觸性皮膚炎的註冊數據(美國)
  • 蛋白質接觸性皮炎-病例報告(西班牙)
  • 日本痤瘡患者過氧化苯甲□引起的過敏性接觸性皮膚炎20例

第22章市場促進因素

第23章市場壁壘

第24章市場准入和醫療費用報銷

  • 美國

第25章SWOT分析

第26章附錄

  • 參考
  • 報告調查方法

第27章:DelveInsight服務內容

第28章免責聲明

第29章:關於Delve Insight

目錄
Product Code: DIMI0406

DelveInsight's 'Contact Dermatitis (CD) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Contact Dermatitis (CD), historical and forecasted epidemiology as well as the Contact Dermatitis (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Contact Dermatitis (CD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Contact Dermatitis (CD) market size from 2017 to 2030. The report also covers current Contact Dermatitis (CD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Contact Dermatitis (CD) Disease Understanding and Treatment Algorithm

Contact Dermatitis (CD) Overview

Contact dermatitis (CD) is a type of eczema triggered by contact with a particular substance in the environment that the person is allergic to, it may react by causing the skin to itch and become red. Eczema is the name for a group of conditions that cause skin to become dry and irritated. CD usually improves or clears up completely if the substance causing the problem is identified and avoided. Treatments are also available to help ease the symptoms.

CD is a common inflammatory skin condition characterized by erythematous and pruritic skin lesions that occur after contact with a foreign substance. The most common substances that cause CD include poison ivy, nickel, and fragrances. CD usually leads to erythema and scaling with visible borders. Itching and discomfort may also occur.

Clinical symptoms depend primarily on whether the dermatitis is acute or chronic, as well as on the toxin involved, type of contact, pathomechanism, and localization, among other factors. Although all types of dermatitis generally share common features, the classic eczematous stages in CD are most readily identifiable.

Acute CD is characterized by pathological symptoms over the entire lesion:

  • Mild form: erythema at the site of exposure to the toxin, contact traces, and itching are possible.
  • Severe form: ranging from vesicular papules to blisters, usually causing strong itching. A feeling of tightness of the skin and even pain may occur. Blister rupture is followed by weeping, scab formation, and later by scaliness. Spreading reactions are possible in the case of an allergic trigger.

CD is a common skin problem occurring in 15-20% of people. Irritant Contact Dermatitis (ICD) is more common (80%) and can occur in anyone, especially after repeated exposure. Allergic contact dermatitis (ACD), on the other hand, is seen in genetically predisposed and previously sensitized individuals who react to even low concentrations of the agent. Cosmetics, medicines, clothes dyes, as well as foods, rubber and poison ivy are common causes of ACD. Any topical cream or ointment may contain chemicals that irritate the skin.

Contact Dermatitis (CD) Diagnosis

The diagnosis of CD is most often made with history and physical examination findings. Irritant and allergic CD may be complicated by bacterial superinfection, and bacterial culture should be considered with the presence of exudate, weeping, and crusting. A potassium hydroxide (KOH) preparation is useful if tinea or Candida infection is suspected, because these fungal infections can have erythema and scaling similar to contact dermatitis. If the KOH preparation has negative results but a fungal etiology is still suspected, a fungal culture should be sent for laboratory testing. Dermoscopy and microscopy can be used to look for scabies and mites.

When a possible causative substance is known, the first step in confirming the diagnosis is observing whether the problem resolves with avoidance of the substance. If avoidance and empiric treatment do not resolve the dermatitis or the allergen remains unknown, patch testing may be indicated. In one study, patch testing had a sensitivity and specificity of between 70-80%. However, it is expensive and time-consuming, and prohibits the patient from showering (a "sponge bath" technique may be used). Patch testing should not be confused with other types of allergy testing. Skin prick and radio-allergosorbent tests are used for the diagnosis of type I hypersensitivity, such as respiratory, latex, and food allergies, but not for contact dermatitis.

In some cases, a repeated open application test (ROAT) is useful, particularly to assess cosmetics. A ROAT involves reapplying the substance onto the same area of skin twice a day for 7 days, to see how the patients' skin reacts. This is a particularly useful way for anyone to check their cosmetics at home for reactions.

Contact Dermatitis (CD) Treatment

In patients with contact dermatitis, the priority is to identify and avoid the causative substance. Cool compresses can soothe the symptoms of acute contact dermatitis, and calamine lotion and colloidal oatmeal baths may help dry and soothe acute, oozing lesions.

Localized acute allergic CD lesions are successfully treated with mid- or high-potency topical steroids, such as triamcinolone 0.1% (Kenalog, Aristocort) or clobetasol 0.05% (Temovate). On areas with thinner skin (e.g., flexural surfaces, eyelids, face, anogenital region), lower-potency steroids, such as desonide ointment (Desowen), can be helpful and minimize the risk of skin atrophy. There are insufficient data to support the use of topical steroids for irritant contact dermatitis. However, because it is difficult to clinically distinguish between allergic and irritant contact dermatitis, these agents are often used successfully for the irritant form as well.

Till date, there is no approved therapy specific for CD. The treatment paradigm is mostly similar to that of Atopic Dermatitis. Therefore, the current treatment of CD is mainly dominated by the use of off-label therapies, which includes Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids and Others (Antiseptics, Topical Antibiotics, Phototherapy and Other Immunosupressants).

Contact Dermatitis (CD) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Contact Dermatitis, Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution, Gender-specific Diagnosed Prevalent Population of Contact Dermatitis, Age-specific Diagnosed Prevalent Population of Contact Dermatitis and Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpse of the Contact Dermatitis (CD) epidemiology in the 7MM.

  • The total diagnosed prevalent population of CD in the 7 major markets was found to be 43,359,201 in 2017.
  • In case of CD in the United States, the diagnosed prevalent cases were found to be 13,786,942 in 2017.
  • It was found that in the United States the number of cases of ICD and ACD were 11,029,554 and 2,757,388 respectively in 2017.
  • In addition, the number of cases of acute, sub-acute and chronic type of CD were 7,611,771, 2,903,530 and 3,271,641 respectively in 2017, in the United States.
  • Gender-specific data of the United States suggests that the number of cases of CD in males and females were 4,825,430 and 8,961,513 respectively in 2017.
  • Age-specific data for CD suggests that in the United States the maximum number of cases of CD were found in the age group of 46-60 with 4,411,822 cases in 2017, while the lowest number of cases were found in the age group 75+ with 275,739 cases in 2017.
  • In the EU5 countries, the diagnosed prevalence of CD was found to be maximum in Germany with 6,645,210 cases, followed by France with 5,481,080 cases in 2017. While, the least number of cases were found in Spain, with 1,982,709 cases in 2017.
  • In Japan, the diagnosed prevalence of CD was found to be 5,107,575 in 2017.

Country Wise- Contact Dermatitis (CD) Epidemiology

The epidemiology segment also provides the Contact Dermatitis (CD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Dermatitis (CD) Drug Chapters

The drug chapter segment of the Contact Dermatitis (CD) report encloses the detailed analysis of Contact Dermatitis (CD) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Contact Dermatitis (CD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Contact Dermatitis (CD) Emerging Drugs

EB01 Cream: Edesa Biotech

EB01 is a novel sPLA2 inhibitor for the topical treatment of chronic ACD. The sPLA2 inhibitors are designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred. The drug inhibits sPLA2 from degrading phospholipids to produce arachidonic acid. Arachidonic acid is processed via the LOX-COX pathway to generate several pro-inflammatory signalling molecules. The drug exerts its anti-inflammatory activity upstream of currently approved NSAIDs, which target the LOX-COX pathway. The FDA accepted Edesa's investigational new drug (IND) application of EB01 for CD patients in November 2018. In June 2019, Edesa Biotech and Stellar Biotechnologies completed share exchange agreement. The combined company, called Edesa Biotech, thereafter, focused on the development and advancement of innovative treatments for dermatological and gastrointestinal indications. In December 2019, the company reported that EB01 had demonstrated positive safety data in healthy volunteers participating in its ongoing phase IIb clinical study in chronic ACD. Considering this positive result, the company expanded the phase IIb dermatitis study to patients with facial lesions. Currently, the drug is still being investigated in phase II clinical developmental trial in the United States for CD.

Product detail in the report…

PDC-APB: Hapten Sciences

PDC-APB is a small molecule that acts like a vaccine to prevent the excruciating itching and rash (CD) caused by exposure to urushiol (yoo-ROO-she-ol) oil in poison ivy, poison oak, and poison sumac plants. Hapten licensed PDC-APB from the University of Mississippi in 2010. In 2015, the company had filed an Investigational New Drug (IND) application of PDC-APB for CD caused by poison ivy, poison oak, and poison sumac plants. The drug has already completed its phase I trial in January 2018 and in June 2019, Hapten Sciences published data regarding attainment of a fourth patent by the University of Mississippi for its investigational product that could prevent the painful itching and rash due to exposure to poison ivy, poison oak, and poison sumac.

Product detail in the report…

Contact Dermatitis (CD) Market Outlook

According to the American Academy of Allergy Asthma and Immunology (AAAAI), the CD is a common skin problem that occurs in ~15-20% of people. It can pose a significant financial burden with direct and indirect costs from lost time off work and school. CD can either be of allergic (ACD) type or irritant (ICD) type. Out of these two, ICD is more common (80%) and can occur in anyone, especially after repeated exposure. Additionally, in 2004, the Society of Investigative Dermatology revealed that ~72.3 million people were suffering from CD in the United States, representing one of the top five most economically burdensome skin diseases.

Since there are no approved therapies for CD, the market is mainly dominated by the use of off-label prescription drugs. Treatments for CD include Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids, and Others (Antiseptics, Topical Antibiotics, Phototherapy, and Other Immunosupressants). However, topical corticosteroids remain the mainstay or the first-line treatment option for CD while phototherapy and systemic immune modulators form the second-line treatment option for the indication.

The American Academy of Allergy, Asthma, and Immunology (AAAAI) has published separate diagnostic and management guidelines for both CD and atopic dermatitis (AD). As per these guidelines, the treatment pattern of both the indications was quite similar. Even though the pathophysiology of AD and CD are extremely different as AD is an immunodeficiency disorder and CD is contact triggered disorder, but the signs and symptoms of both the diseases are quite similar that justifies the same prescription pattern as well. Keeping this in mind, the US CD market forecast considers AD prescription pattern.

However, the current emerging market of CD does not possess a robust pipeline. There is only one therapy, EB01 Cream, which is in its phase II developmental stage. Additionally, there is another therapy, namely, PDC-APB that has completed its phase I trial and was licensed by Hapten from the University of Mississippi in 2010. The phase I trial of PDC-APB was completed in January 2018 itself; however, the results of this trial has not been published yet. Therefore, Hapten's PDC-APB has not been considered in the forecast model of CD report.

Key Findings

This section includes a glimpse of the Contact Dermatitis (CD) 7MM market.

  • The market size of CD in the seven major markets was estimated to be USD 7,831 Million in 2017.
  • The United States accounts for the largest market size of CD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
  • Among the EU5 countries, Germany had the highest market size with USD 981 Million in 2017, while Spain had the lowest market size of CD with USD 293 Million in 2017.
  • The Japan CD market accounted for USD 752 Million in 2017, which is expected to increase during the forecast period of 2020-2030.

The United States Market Outlook

This section provides the total Contact Dermatitis (CD) market size and market size by therapies in the United States.

EU-5 Market Outlook

The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Contact Dermatitis (CD) market size and market size by therapies in Japan are provided.

Contact Dermatitis (CD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Contact Dermatitis (CD) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Contact Dermatitis (CD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Contact Dermatitis (CD) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Contact Dermatitis (CD) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Contact Dermatitis (CD) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Contact Dermatitis (CD), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Contact Dermatitis (CD) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Contact Dermatitis (CD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Contact Dermatitis (CD) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Contact Dermatitis (CD) market.

Report Highlights:

  • In the coming years, Contact Dermatitis (CD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Contact Dermatitis (CD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • DelveInsight has analyzed type-based data for Contact Dermatitis (CD). Contact Dermatitis can be of two types based on this data, namely, Irritant Contact Dermatitis (ICD) and Allergic Contact Dermatitis (ACD).
  • Type-specific data based on clinical and biological evolution of Contact Dermatitis (CD) has also been analyzed by Delvelnsight. On this basis, Contact Dermatitis can be divided as Acute, Sub-acute and Chronic type.
  • In addition, Delvelnsight has also analyzed gender-specific data for Contact Dermatitis (CD), which clearly suggests that CD is more prevalent among females than males.
  • The report also encompasses another major segment, i.e., Age-specific Diagnosed Prevalent Population of Contact Dermatitis (CD), wherein various age groups have been considered, such as 0-17, 18-29, 30-45, 46-60, 61-75 and 75+. It has been found that CD majorly affects patients whose age is 40 years or above.
  • Expected Launch of a potential therapy, EB01 (Edesa Biotech), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Contact Dermatitis (CD).
  • The current treatment of Contact Dermatitis (CD) is mainly dominated by the use of off-label therapies, which includes Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids and Others (Antiseptics, Topical Antibiotics, Phototherapy and Other Immunosupressants).

Contact Dermatitis (CD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Contact Dermatitis (CD) Pipeline Analysis
  • Contact Dermatitis (CD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Contact Dermatitis (CD) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Contact Dermatitis (CD) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Contact Dermatitis (CD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Contact Dermatitis (CD) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Contact Dermatitis (CD) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Contact Dermatitis (CD) market size during the forecast period (2020-2030)?
  • At what CAGR, the Contact Dermatitis (CD) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Contact Dermatitis (CD) market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Contact Dermatitis (CD) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Contact Dermatitis (CD)?
  • What is the historical Contact Dermatitis (CD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Contact Dermatitis (CD) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Contact Dermatitis (CD)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Contact Dermatitis (CD) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Contact Dermatitis (CD) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Contact Dermatitis (CD) in the US and Europe?
  • What are the Contact Dermatitis (CD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Contact Dermatitis (CD)?
  • How many therapies are developed by each company for the treatment of Contact Dermatitis (CD)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Contact Dermatitis (CD)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Contact Dermatitis (CD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Contact Dermatitis (CD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Contact Dermatitis (CD)?
  • What are the 7MM historical and forecasted market of Contact Dermatitis (CD)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Contact Dermatitis (CD).
  • To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Contact Dermatitis (CD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Contact Dermatitis (CD) market.
  • To understand the future market competition in the Contact Dermatitis (CD) market.

Table of Contents

1 Key Insights

2 Contact Dermatitis Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of Contact Dermatitis in 2017
  • 2.2 Market Share (%) Distribution of Contact Dermatitis in 2030

3 Executive Summary of Contact Dermatitis (CD)

4 Disease Background and Overview: Contact Dermatitis (CD)

  • 4.1 Types
    • 4.1.1 Irritant Contact Dermatitis (ICD)
    • 4.1.2 Allergic Contact Dermatitis (ACD)
    • 4.1.3 Contact Urticaria
  • 4.2 Causes
    • 4.2.1 Metals
    • 4.2.2 Fragrances
    • 4.2.3 Antibacterial Ointments
    • 4.2.4 Formaldehyde
    • 4.2.5 Isothiazolinones
    • 4.2.6 Cocamidopropyl Betaine
    • 4.2.7 Paraphenylene-Diamine
  • 4.3 Symptoms
  • 4.4 Pathophysiology
  • 4.5 Diagnosis

5 Algorithm for Diagnosis and Management of CD

6 Diagnostic Guidelines by American Academy of Allergy Asthma & Immunology (AAAAI)

  • 6.1 Clinical Evaluation
  • 6.2 Patch testing recommendations
  • 6.3 Sources of exposure to clinically relevant allergens
  • 6.4 Topical medicinal CD
  • 6.5 Special populations
    • 6.5.1 CD in children
    • 6.5.2 Occupational CD

7 Diagnostic Guidelines by the British Association of Dermatologists (BAD)

  • 7.1 Assessment and Investigation
  • 7.2 Diagnostic Tests (Diagnosis)
    • 7.2.1 Preparation of the patient
    • 7.2.2 Patch testing
    • 7.2.3 Timing of patch test readings
    • 7.2.4 Reading and relevance of positive reactions
    • 7.2.5 Photopatch testing
    • 7.2.6 Open patch testing

8 Epidemiology and Patient Population: Key Findings

  • 8.1 7MM 7MM Total Diagnosed Prevalent Population of Contact Dermatitis

9 Country Wise-Epidemiology of Contact Dermatitis

  • 9.1 United States
    • 9.1.1 Assumptions and Rationale
    • 9.1.2 Total Diagnosed Prevalent Population of Contact Dermatitis in the United States
    • 9.1.3 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United States
    • 9.1.4 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
    • 9.1.5 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
    • 9.1.6 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
  • 9.2 EU5 Countries
    • 9.2.1 Assumptions and Rationale
  • 9.3 Germany
    • 9.3.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Germany
    • 9.3.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Germany
    • 9.3.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
    • 9.3.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
    • 9.3.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
  • 9.4 France
    • 9.4.1 Total Diagnosed Prevalent Population of Contact Dermatitis in France
    • 9.4.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in France
    • 9.4.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in France
    • 9.4.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in France
    • 9.4.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in France
  • 9.5 Italy
    • 9.5.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Italy
    • 9.5.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Italy
    • 9.5.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
    • 9.5.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
    • 9.5.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
  • 9.6 Spain
    • 9.6.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Spain
    • 9.6.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Spain
    • 9.6.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
    • 9.6.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
    • 9.6.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
  • 9.7 United Kingdom
    • 9.7.1 Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
    • 9.7.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United Kingdom
    • 9.7.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
    • 9.7.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
    • 9.7.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
  • 9.8 Japan
    • 9.8.1 Assumptions and Rationale
    • 9.8.2 Total Diagnosed Prevalent Population of Contact Dermatitis in Japan
    • 9.8.3 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Japan
    • 9.8.4 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan
    • 9.8.5 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan
    • 9.8.6 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan

10 Treatment

11 Contact Dermatitis: A Practice Parameter - Update 2015

  • 11.1 Treatment of CD

12 British Association of Dermatologists (BAD) Guidelines for the Management of CD 2017

  • 12.1 Management/Treatment Options
    • 12.1.1 Avoidance
    • 12.1.2 Protection
    • 12.1.3 Substitution
    • 12.1.4 Treatment of Persistent CD

13 Recognized Establishments

14 Unmet Needs

15 Emerging Drugs

  • 15.1 Key-cross Competition
  • 15.2 EB01 Cream: Edesa Biotech
    • 15.2.1 Product Description
    • 15.2.2 Other Developmental Activities
    • 15.2.3 Clinical Development
    • 15.2.4 Safety and Efficacy
    • 15.2.5 Product Profile
  • 15.3 PDC-APB: Hapten Sciences
    • 15.3.1 Product Description
    • 15.3.2 Other Developmental Activities
    • 15.3.3 Clinical Development
    • 15.3.4 Safety and Efficacy
    • 15.3.5 Product Profile

16 Contact Dermatitis: 7 Major Market Analysis

  • 16.1 Key Findings
  • 16.2 Market Size of Contact Dermatitis in the 7MM

17 The United States Market Outlook

  • 17.1 United States Market Size
    • 17.1.1 Total Market size of Contact Dermatitis
    • 17.1.2 Market Size by Therapies

18 EU-5 Countries: Market Outlook

  • 18.1 Germany
    • 18.1.1 Total Market size of Contact Dermatitis
    • 18.1.2 Market Size by Therapies
  • 18.2 France
    • 18.2.1 Total Market size of Contact Dermatitis
    • 18.2.2 Market Size by Therapies
  • 18.3 Italy
    • 18.3.1 Total Market size of Contact Dermatitis
    • 18.3.2 Market Size by Therapies
  • 18.4 Spain
    • 18.4.1 Total Market size of Contact Dermatitis
    • 18.4.2 Market Size by Therapies
  • 18.5 The United Kingdom
    • 18.5.1 Total Market size of Contact Dermatitis
    • 18.5.2 Market Size by Therapies

19 Japan Market Outlook

  • 19.1 Japan Market Size
    • 19.1.1 Total Market size of Contact Dermatitis
    • 19.1.2 Market Size by Therapies

20 KOL Reviews

21 Case Reports

  • 21.1 Pediatric Contact Dermatitis Registry Data on Contact Allergy in Children with Atopic Dermatitis (United States)
  • 21.2 Protein contact dermatitis - Case report (Spain)
  • 21.1 Twenty cases of allergic contact dermatitis due to benzoyl peroxide in acne patients in Japan

22 Market Drivers

23 Market Barriers

24 Market Access and Reimbursement

  • 24.1 United States

25 SWOT Analysis

26 Appendix

  • 26.1 Bibliography
  • 26.2 Report Methodology

27 DelveInsight Capabilities

28 Disclaimer

29 About DelveInsight

List of Tables

  • Table 1: Summary of Contact Dermatitis, Market, Epidemiology and Key Events (2017-2030)
  • Table 2: Classical clinical forms of CD
  • Table 3: Features that distinguishes between Irritant and Allergic Contact Dermatitis
  • Table 4: Exogenous and endogenous factors affecting clinical characteristics of CD
  • Table 5: The most important non-eczematous symptoms of contact allergic reactions
  • Table 6: Differential Diagnosis of Contact Dermatitis
  • Table 7: Scoring of patch test reactions according to the International Contact Dermatitis Research Group recommendations
  • Table 8: Total Diagnosed Prevalent Population of Contact Dermatitis in the 7MM (2017-2030)
  • Table 9: Total Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Table 10: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in the US (2017-2030)
  • Table 11: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Table 12: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Table 13: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Table 14: Total Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Table 15: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Germany (2017-2030)
  • Table 16: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Table 17: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Table 18: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Table 19: Total Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Table 20: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in France (2017-2030)
  • Table 21: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Table 22: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Table 23: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Table 24: Total Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Table 25: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Italy (2017-2030)
  • Table 26: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Table 27: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Table 28: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Table 29: Total Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Table 30: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Spain (2017-2030)
  • Table 31: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Table 32: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Table 33: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Table 34: Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Table 35: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in the UK (2017-2030)
  • Table 36: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Table 37: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Table 38: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Table 39: Total Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
  • Table 40: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Japan (2017-2030)
  • Table 41: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
  • Table 42: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
  • Table 43: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
  • Table 44: Comparison of emerging drugs under development
  • Table 45: EB01 Cream, Clinical Trial Description, 2020
  • Table 46: Percent Change from Baseline to Day 21
  • Table 47: PDC-APB, Clinical Trial Description, 2020
  • Table 48: 7 Major Market Size of Contact Dermatitis in USD Million (2017-2030)
  • Table 49: Total Market Size of Contact Dermatitis in the United States, in USD Million (2017-2030)
  • Table 50: Market size of Contact Dermatitis by therapies in the United States, in USD Million (2017-2030)
  • Table 51: Total Market Size of Contact Dermatitis in Germany, in USD Million (2017-2030)
  • Table 52: Market size of Contact Dermatitis by therapies in Germany, in USD Million (2017-2030)
  • Table 53: Total Market Size of Contact Dermatitis in France, in USD Million (2017-2030)
  • Table 54: Market size of Contact Dermatitis by therapies in France, in USD Million (2017-2030)
  • Table 55: Total Market Size of Contact Dermatitis in Italy, in USD Million (2017-2030)
  • Table 56: Market size of Contact Dermatitis by therapies in Italy, in USD Million (2017-2030)
  • Table 57: Total Market Size of Contact Dermatitis in Spain, in USD Million (2017-2030)
  • Table 58: Market size of Contact Dermatitis by therapies in Spain, in USD Million (2017-2030)
  • Table 59: Total Market Size of Contact Dermatitis in the United Kingdom, in USD Million (2017-2030)
  • Table 60: Market size of Contact Dermatitis by therapies in the United Kingdom, in USD Million (2017-2030)
  • Table 61: Total Market Size of Contact Dermatitis in Japan, in USD Million (2017-2030)
  • Table 62:Market size of Contact Dermatitis by therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1: Pathophysiology of Allergic and Irritant CD
  • Figure 2: Algorithm for Diagnosis and Management of CD
  • Figure 3: Total Diagnosed Prevalent Population of Contact Dermatitis in the 7MM (2017-2030)
  • Figure 4: Total Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017-2030)
  • Figure 5: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United States (2017-2030)
  • Figure 6: Gender-specific Diagnosed Prevalent Population of CD in the United States (2017-2030)
  • Figure 7: Age-specific Diagnosed Prevalent Population of CD in the United States (2017-2030)
  • Figure 8: Type-specific Diagnosed Prevalent Population of CD in the United States (2017-2030)
  • Figure 9: Total Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017-2030)
  • Figure 10: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Germany (2017-2030)
  • Figure 11: Gender-specific Diagnosed Prevalent Population of CD in Germany (2017-2030)
  • Figure 12: Age-specific Diagnosed Prevalent Population of CD in Germany (2017-2030)
  • Figure 13: Type-specific Diagnosed Prevalent Population of CD in Germany (2017-2030)
  • Figure 14: Total Diagnosed Prevalent Population of Contact Dermatitis in France (2017-2030)
  • Figure 15: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in France (2017-2030)
  • Figure 16: Gender-specific Diagnosed Prevalent Population of CD in France (2017-2030)
  • Figure 17: Age-specific Diagnosed Prevalent Population of CD in France (2017-2030)
  • Figure 18: Type-specific Diagnosed Prevalent Population of CD in France (2017-2030)
  • Figure 19: Total Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017-2030)
  • Figure 20: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Italy (2017-2030)
  • Figure 21: Gender-specific Diagnosed Prevalent Population of CD in Italy (2017-2030)
  • Figure 22: Age-specific Diagnosed Prevalent Population of CD in Italy (2017-2030)
  • Figure 23: Type-specific Diagnosed Prevalent Population of CD in Italy (2017-2030)
  • Figure 24: Total Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017-2030)
  • Figure 25: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Spain (2017-2030)
  • Figure 26: Gender-specific Diagnosed Prevalent Population of CD in Spain (2017-2030)
  • Figure 27: Age-specific Diagnosed Prevalent Population of CD in Spain (2017-2030)
  • Figure 28: Type-specific Diagnosed Prevalent Population of CD in Spain (2017-2030)
  • Figure 29: Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017-2030)
  • Figure 30: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United Kingdom (2017-2030)
  • Figure 31: Gender-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017-2030)
  • Figure 32: Age-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017-2030)
  • Figure 33: Type-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017-2030)
  • Figure 34: Total Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017-2030)
  • Figure 35: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Japan (2017-2030)
  • Figure 36: Gender-specific Diagnosed Prevalent Population of CD in Japan (2017-2030)
  • Figure 37: Age-specific Diagnosed Prevalent Population of CD in Japan (2017-2030)
  • Figure 38: Type-specific Diagnosed Prevalent Population of CD in Japan (2017-2030)
  • Figure 39: Unmet Needs of Contact Dermatitis
  • Figure 40: 7 Major Market Size of Contact Dermatitis in USD Million (2017-2030)
  • Figure 41: Total Market Size of Contact Dermatitis in the United States, USD Millions (2017-2030)
  • Figure 42: Market size of Contact Dermatitis by therapies in the United States, in USD Million (2017-2030)
  • Figure 43: Total Market Size of Contact Dermatitis in Germany, USD Millions (2017-2030)
  • Figure 44: Market size of Contact Dermatitis by therapies in Germany, in USD Million (2017-2030)
  • Figure 45: Total Market Size of Contact Dermatitis in France, USD Millions (2017-2030)
  • Figure 46: Market size of Contact Dermatitis by therapies in France, in USD Million (2017-2030)
  • Figure 47: Total Market Size of Contact Dermatitis in Italy, USD Millions (2017-2030)
  • Figure 48: Market size of Contact Dermatitis by therapies in Italy, in USD Million (2017-2030)
  • Figure 49: Total Market Size of Contact Dermatitis in Spain, USD Millions (2017-2030)
  • Figure 50: Market size of Contact Dermatitis by therapies in Spain, in USD Million (2017-2030)
  • Figure 51: Total Market Size of Contact Dermatitis in the United Kingdom, USD Millions (2017-2030)
  • Figure 52: Market size of Contact Dermatitis by therapies in the United Kingdom, in USD Million (2017-2030)
  • Figure 53: Total Market Size of Contact Dermatitis in Japan, USD Millions (2017-2030)
  • Figure 54: Market size of Contact Dermatitis by therapies in Japan, in USD Million (2017-2030)
  • Figure 55: Market Drivers
  • Figure 56: Market Barriers
  • Figure 57:SWOT Analysis